Unlabelled: Accelerated partial breast irradiation via brachytherapy (APBI-b) is offered as an alternative to whole breast irradiation (WBI) for selected patients with breast cancer. This study evaluates our clinical experience with APBI-b to identify the reasons for decreased clinical utilization in recent years. We performed an analysis of the prospective database of breast cancer patients treated with APBI-b between 2004 and 2013. During that time, 245 patients received APBI-b, most having stage I (77%) or stage 0 (20%) breast cancer. Since 2004, the number of APBI-b cases per year rose to 49 in 2009, declining thereafter to 14 in 2013 (P < 0.001). The APBI-b case volume dropped in 2010 following the publication of the American Society of Radiation Oncology (ASTRO) consensus guidelines in 2009. After 2009 fewer unsuitable cases received APBI-b (11% vs. 4%,P = 0.1).
Conclusion: The clinical utilization of APBI-b has decreased after the publication of consensus guidelines. A reduction in unsuitable cases treated after 2009 does not explain the global loss of referrals.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Survival Among Patients With ERBB2-Positive Metastatic Breast Cancer and Central Nervous System Disease.
JAMA Netw Open
January 2025
Department of Neurosurgery and Brain Metastasis Center, Memorial Sloan Kettering Cancer Center, New York, New York.
Importance: Approximately one-third of patients with ERBB2 (formerly HER2 or HER2/neu)-positive (ERBB2+) metastatic breast cancer (MBC) develop brain metastasis. It is unclear whether patients with disease limited to the central nervous system (CNS) have different outcomes and causes of death compared with those with concomitant extracranial metastasis.
Objective: To assess overall survival (OS) and CNS-related mortality among patients with ERBB2+ breast cancer and a diagnosis of CNS disease by disease distribution (CNS only vs CNS plus extracranial metastasis).
Measuring patient reported outcomes in brachytherapy: Why we should do it and more importantly how.
Clin Transl Radiat Oncol
November 2024
Royal Surrey Hospital, Guildford, UK.
As the treatment for cancer improves and advances are made, the clinical focus is often on treatment response and survival. However, these are not the only factors which are important to patients. More patients are living longer after cancer treatment and therefore it is important that we can describe not only the treatment to patients but also what their life will be like during and after treatment.
View Article and Find Full Text PDFPurpose: Radiation protection glasses reduce eye lens exposure in Interventional Radiology (IR). However, the protection ratio differs for the lead equivalent content and shape of the lenses. This study aimed to examine factors effective in reducing the lens dose by measuring the protection ratio of scattered radiation due to changes in the surgeon's face orientation, various lead equivalents, and shapes.
View Article and Find Full Text PDFRisk of Subclinical Hypothyroidism in Breast Cancer Patients Treated With CT-Guided Radiation Therapy: A Prospective Observational Study.
Clin Epidemiol
January 2025
Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
Purpose: The thyroid gland is an organ at risk in breast cancer survivors who receive radiation therapy to the supraclavicular lymph nodes. We investigated the effect of radiation dose to the thyroid gland on the incidence of hypothyroidism in early-stage breast cancer patients treated with CT-guided radiation therapy.
Patients And Methods: We recruited women aged ≤75 years diagnosed with breast cancer from March 2016 through August 2017 at Odense University Hospital, Denmark.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!